Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to their growth and progression. Checkpoint inhibitor pathways act as the checks and balances that allow T-cells to recognize foreign substances or tumors. This global study looks at the immune-oncology therapeutics pipeline for checkpoint inhibitors in the drug classes CTLA-4, PD-1/PD-L1, LAG-3, and TIM-3, identifying companies and products in development, dollars spent at each phase (preclinical through launch), cost and reimbursement implications to payers, challenges to commercialization, and opportunities for pharmaceutical, biotech, or diagnostic companies as oncology treatment algorithms evolve. The study period is 2011 to 2020.
Key Questions this Study will Answer
- What checkpoint therapies are in development and for what indications?
- What products and indications will be launched in the next 5 years?
- Who is investing in the development of checkpoint inhibitors, at what phase, and at what level of deal funding?
- What are some of the cost implications for checkpoint therapies, especially when combined with other immuno-oncology therapies?
- What are the challenges to development and commercialization of checkpoint inhibitors?
- What challenges do payers face related to the high cost of specialty therapeutics?